Showing 4661-4670 of 5957 results for "".
- Novartis Acquires Arctos Medical, Expanding Optogenetics Portfoliohttps://modernod.com/news/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-to-bring-gene-therapies-to-patients-with-severe-vision-loss/2480291/Novartis announced that it has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Financial terms of the deal were not disclosed. “Optogenetics is emergi
- Glaukos Announces Licensing Agreement with Attillaps Holdingshttps://modernod.com/news/glaukos-announces-licensing-agreement-with-attillaps-holdings-inc/2480289/Glaukos announced that it has entered into a licensing agreement with Attillaps Holdings under which Glaukos will gain a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compound
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- Voptica Introduces Inverted Meniscus IOL to Improve Peripheral Vision at ESCRShttps://modernod.com/news/voptica-introduces-inverted-meniscus-iol-to-improve-peripheral-vision-at-escrs/2480285/Voptica SL has introduced what it is calling the first and only inverted meniscus intraocular lens (ArtIOLs) to improve peripheral vision, according to a company news release. Introduced at the 2021 ESCRS symposium in Amsterdam, ArtIOLs mimic the optics of the natural cry
- Luneau Technology and Optovue Announce Mergerhttps://modernod.com/news/luneau-technology-and-optovue-announce-merger/2480284/France-based Luneau Technology Group, a provider of wavefront-based diagnostic and finishing solutions, announced it is merging with Optovue. Terms of the deal were not disclosed. Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology
- Sight Sciences Files Lawsuit Against Ivantis for Patent Infringementhttps://modernod.com/news/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement/2480283/Sight Sciences announced that it has filed a lawsuit in the United States District Court in Delaware against Ivantis for infringement of U.S. Patents that describe and claim devices and methods for reducing intraocular pressure in the eye. The patents are Numbers 8,287,48
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-eye-care-collaboration/2479577/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patient
- World Council of Optometry Launches Myopia Management Online Resourcehttps://modernod.com/news/world-council-of-optometry-launches-myopia-management-online-resource/2479506/Building upon their efforts to establish a standard of care for myopia management, the World Council of Optometry (WCO) and CooperVision have jointly developed an easy-to-use online resource that provides multilingual assets and approaches that will enable busy eye care professionals—regardless o